AU663373B2 - Creación de Inventos y Patentes con Inteligencia Artificial

AU663373B2 – Method for preventing and treating atherosclerosis
– Google Patents

AU663373B2 – Method for preventing and treating atherosclerosis
– Google Patents
Method for preventing and treating atherosclerosis

Download PDF
Info

Publication number
AU663373B2

AU663373B2
AU38387/93A
AU3838793A
AU663373B2
AU 663373 B2
AU663373 B2
AU 663373B2
AU 38387/93 A
AU38387/93 A
AU 38387/93A
AU 3838793 A
AU3838793 A
AU 3838793A
AU 663373 B2
AU663373 B2
AU 663373B2
Authority
AU
Australia
Prior art keywords
patient
product
atherosclerosis
administered
oxothiazolidine
Prior art date
1992-08-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU38387/93A
Other versions

AU3838793A
(en

Inventor
Dennis I. Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Transcend Therapeutics Inc

Original Assignee
Free Radical Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1992-08-17
Filing date
1993-05-05
Publication date
1995-10-05

1993-05-05
Application filed by Free Radical Sciences Corp
filed
Critical
Free Radical Sciences Corp

1994-02-24
Publication of AU3838793A
publication
Critical
patent/AU3838793A/en

1994-06-09
Assigned to FREE RADICAL SCIENCES, INC.
reassignment
FREE RADICAL SCIENCES, INC.
Alteration of Name(s) of Applicant(s) under S113
Assignors: CLINTEC NUTRITION COMPANY

1995-10-05
Application granted
granted
Critical

1995-10-05
Publication of AU663373B2
publication
Critical
patent/AU663373B2/en

1996-01-04
Assigned to TRANSCEND THERAPEUTICS, INC
reassignment
TRANSCEND THERAPEUTICS, INC
Amend patent request/document other than specification (104)
Assignors: FREE RADICAL SCIENCES, INC.

2013-05-05
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/33—Heterocyclic compounds

A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins

A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

A61K31/425—Thiazoles

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P9/00—Drugs for disorders of the cardiovascular system

A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Description

F-
i 663373 p00011 Regulation 3.2
AUSTRALIA
Patents Act, 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT Original r I ~r cc r t rr I cc r I r r cc t rr cc r r r cc rr II r t tute i TO BE COMPLETED BY THE APPLICANT -eLiifTec NUTrITieiN ci4PaN’: if aL NAME OF APPLICANT: ACTUAL INVENTOR: ADDRESS FOR SERVICE: INVENTION TITLE: DENNIS I. GOLDBERG Peter Maxwell Associates Blaxland House, Suite 10, 5 Ross Street, NORTH PARRAMATTA NSW 2151 METHOD FOR PREVENTING AND TREATING
ATHEROSCLEROSIS
The following statement is a full description of this invention, including the best method of performing it know to me:a la SThe present invention relates generally to the treatment of cardiovascular disease. More specifically, the present invention relates to treatment of atherosclerosis.
Cardiovascular disease is the leading cause of death in the United States. In the United States, of a population of 226.5 million in 1980, 551,400 died of ischemic heart disease and 169,500 died of o ^cerebrovascular causes related to arterial disease. See, 0 Merck Manual, Fifteenth Edition, pp. 386.
Atherosclerosis is a form of arteriosclerosis marked .by the formation of atheromas. The disease causes the lumen of an artery to become narrowed or blocked I (occluded). The atheroma obstructs circulation by protruding into the arterial lumen. The narrowing of the artery restricts blood flow to the organ that is nourished by the artery. The reduced blood flow results i .in the deterioration of the organ to the point wherein the organ can be permanently damaged unless the blockage of blood flow is removed. When an artery that serves the heart is narrowed or blocked, this pathological process results in a heart attack. i The relationship between hypercholesterolemia, abnormal lipoprotein profiles, and atherogenesis has been well defined. More recently, oxidative modification of lipoproteins, lipoprotein and induction of cytokines and growth factors have been implicated as important factors in the initiation and progression of atherosclerotic plaques.
I-
2 Lipid peroxidation is one of the deleterious effects of oxidative stress. Peroxidation of the unsaturated lipid moieties of lipoproteins results in a sequelae of events yielding oxidatively modified lipoproteins and macrophage derived foam cells. These cells, which constitute a significant portion of the cells within atherosclerotic lesions, phagocytose and degrade oxidatively modified lipoproteins. See, Rosenfeld et al., Macrophage-derived Foam Cells Freshly Isolated from Rabbit Atherosclerotic Lesions Degrade Modified
I
I
I
Lipoproteins, Promote Oxidation of Low-Density Lipoproteins, and Contain Oxidation-specific Lipid- Protein Adducts, J. Clin. Invest., Vol. 87, pp. 90-99 (1991).
A number of pharmaceutical interventions have been proposed for treating and/or preventing atherosclerosis.
Although the logic of attempting to protect against lipoprotein modification and ensuing lipid hydroperoxide generation may be apparent, the role of glutathione as providing antioxidant protection is at best unsettled.
Heinecke et al., i’he Role of Sulfur-containing Amino Acids in Superoxide Production and Modification of Low Density Lipoprotein by Arterial Smooth Muscle Cells, J.
Biol. Chem., Vol. 262, pp. 10098-10103, 1987, reported that monkey arterial smooth muscle cells produce reactive oxygen species and modify low density lipoprotein by an L-cysteine dependent process. This effect was postulated to involve the production of reduced thiols from the cystine, followed by thiol mediated modification of the lipoprotein.
Parthasarathy, Oxidation of Low-density Lipoprotein by Thiol Compounds Leads to its Recognition by the Acetyl LDL Receptor, Biochim. et Biophys. Acta, Vol. 917, pp.
-I-
ii 3 r, r r rr ri r t r It Ir r c r r ti
I
337-340, 1987 also demonstrated that reduced glutathione and other compounds with reduced thiols promote the oxidation of LDL in the absence of cells. This reaction was hypothesized to be the result of thiol reaction with redox metals, generating free radicals which promote modification of LDL. Parthasarathy further notes: «There appears to be some correlation among plasma cholesterol levels, incidence of atherosclerosis, and levels of protein-bound-homocysteine. Cysteine and other thiols, including protein-bound thiols, undergo auto-oxidation in the presence of redox metals, generating peroxide, superoxide anion and hydroxy radicals in addition to thiol-derived free radicals.» See pp. 339.
In many cases of atherosclerosis, invasive 15 procedures such as bypass surgery or angioplasty are required to reestablish an occluded lumen to proper diameter.
Due to its intrusive nature, bypass surgery inherently has a number of disadvantages. Accordingly, the popularity of angioplasties has increased dramatically. In the United States in 1989, hundreds of thousands of angioplasties were performed. This number is rapidly increasing. Fortunately, for many patients, angioplasty permanently reopens the previously occluded arteries. However, in approximately 30% of the occluded arteries which are opened by an angioplasty technique, the arteries re-occlude within six months of the procedure. This results in symptoms of cardiac ischemia, such as chest pain, exercise intolerance, and shortness of breath. The patient’s risk of disabling or fatal heart attack is markedly increased.
It is believed that re-stenosis in a previously treated segment of an artery is due, at least in part, 4 -4to the stretch-induced damage of arterial tissue. The response to the damagc caused by the inflation of a balloon catheter is an exaggerated healing response that includes proliferation of the endothelial cells.
Likewise, even in bypass surgery there is a danger of re-stenosis in the patient. Bypass grafts in 40% of patients restenose within 5 years of the surgical procedure.
The present invention provides a method of treating atherosclerosis. More specifically, the present invention provides a method of preventing the initiation and/or progression of atherosclerotic lesions. Furthermore, the present invention provides a method for preventing the reit S stenosis of coronary vessels following angioplasty or bypass surgery.
S 1,5 According to one aspect of the invention there is j provided a method for treating atherosclerosis comprising the step of administering to a patient having atherosclerosis a therapeutically effective amount of a product comprising L-2oxothiazolidine-4-carboxylic acid or a salt thereof.
According to another aspect of the invention there is provided a method for preventing atherosclerotic lesions in a f patient at risk of same comprising the steps of administering to the patient a therapeutically effective amount of a product comprising L-2-oxothiazolidine-4-carboxylic acid or a salt thereof.
According to a still further aspect of the invention
II-
r .t i
I:
-Cp- I~ -C~CI ii there is provided a method for preventing re-stenosis in a patient undergoing an invasive procedure to treat atherosclerosis comprising the steps of administering to the patient prior to and after the invasive procedure a therapeutically effective amount of a product comprising L-2oxothiazolidine-4-carboxylic acid or a salt thereof.
The methods of the invention may be carried out by administering the product enterally or parenterally.
In a preferred form of the invention, the product is administered with an amino acid solution.
Additional features and advantages of the present invention are described in, and will be apparent from, the detailed description of the presently preferred embodiments.
The present invention relates to a method of treating atherosclerosis in a patient having same. Furthermore, the present invention relates to a method for preventing atherosclerotic lesions in a patient at risk of same. Still further, the present invention provides a method of preventing re-stenosis in a patient who has undergone an invasive procedure such as angioplasty or bypass surg ry.
To this end, the prevent invention provides a method of treating atherosclerosis comprising the step of administering to patient a non-thiol, non-cysteine, intracellular glutathione stimulator.
As used herein, «non-cysteine» means that the composition does include cysteine. Accordingly, i. .e fi I 6 compositions excluded from this definition, include, cysteine and n-acetylcysteine.
Of course, thiols are sulfur analogs of alcohols and phenols. As used herein, «non-thiol» means that the compound does not contain such a sulfur analog.
Atherogenesis is in many ways an inflammatory reaction in the artarial wall. The chain reaction of lipid peroxidatioi can be blocked by the action of phospholipid hydroperoxide glutathione peroxidase, a second selenoperoxidase, similar to the classic glutathione peroxidase, but which acts upon membrane lipid and cholesterol hydroperoxides. Since glutathione i peroxidase is one of the primary defense mechanisms against lipid hydroperoxides, stimulation of I 15 intracellular glutathione synthesis may prevent the initiation, or break the cycle, of lipid peroxidation believed to be the cause of oxidative lipoprotein modification. This thereby prevents one of the initiating events in atherosclerosis formation.
Vascular endothelial cells, which form an impermeable barrier to lipoprotein infiltration to the subendothelial space, can be damaged by membrane lipid peroxidation. This damage, which can be caused by reactive oxygen species generated within endothelial cells, in lipoproteins, or generated by neutrophils, can lead to further damage of the arterial wall by promoting the adhesion and activation of neutrophils and platelet aggregation.
Adhesion of circulating monocytes and lymphocytes to the endothelial lining is one of the earliest detectable events in animal models of experimental atherosclerosis. The cells subsequently become engorged with lipids and begin to secrete cytokines and growth i 1- ii i ;i -I L.
I I I I 7 ~4 44 I C( factors which exacerbate the injury. The inflammatory process is promoted by cytokine activation of nuclear transcription factor kB (NF-kB). This transcription factor is known to control the expression of a number of genes that code for cytokines and other proteins involved in the inflammatory process.
In fact, most inflammatory agents activate this transcription factor, which then induces agnes that contribute to local inflammatory reactions and lymphocyte activation. Among the proteins induced by inflammation are a variety of adhesion molecules for polymorphonuclear and mononuclear leukocytes. A rabbit homolog of the human adhesion molecule VCAM-1 has recently been identified in the aortic endothelium that covers early foam cell lesions.
Intracellular free radicals and hydrogen peroxides may serve as second messengers, transducing the cytokine signal to activate NF-kB. The activation of NF-kB by a variety of pro-inflammatory cytokines, including interleukin-l. Lipopolysaccharide, lectin, TNF-a, phorbol ester and calcium ionophore, can be blocked by thiol containing compounds. Elevation of intracellular glutathione levels has been demonstrated to prevent the induction of HIV replication by NF-kB. The inventor 25 believes that this data supports the hypothesis that maintaining intracellular glutathione levels may prevent the induction of proinflammatory genes and thereby slow or prevent the initiation and expansion of atherosclerotic lesions.
Although the art would suggest to one that the role of glutathione as a treatment of atherosclerosis is, at best, unclear and perhaps contraindicated, the inventor 1* 1* I 8 has discovered how beneficial effects of glutathione can be used without the disadvantages described supra.
Since the elevation of intracellular glutathione may be beneficial in preventing atherosclerosis, while extracellular thiols may exacerbate lipoprotein modification due to a thiol/redox reaction generation of free radicals, pursuant to the method of the present invention intracellular glutathione synthesis is stimulated by a non-cysteine, non-thiol precursor.
An example of such an agent is L-2-oxothiazolidine- 4-carboxylate. Likewise, other non-cysteine, non-thiol intracellular stimulators can be used, e.g. other S I’ thiazolidine-4-carboxylate analogs.
L-2-oxothiazolidine-4-carboxylate, in vivo, is l 15 subjected to the action of 5-oxo-L-prolinase in the presence of adenosine triphosphate to produce S-carboxyl cysteine. S-carboxyl cysteine is then decarboxylated to produce cysteine. Cysteine is then metabolized to i produce glutathione. See, U.S. Patent Nos.: 4,335,210; 4,434,158; 4,438,124; 4,647,571; and 4,665,082, the disclosures of which are incorporated herein by reference. Due to the intracellular synthesis of both the cysteine and the glutathione the disadvantages noted in the art with respect to cysteine and thiols is not a concern.
An example of a composition that can be administered to the patient is 3% w:v L-2-oxothiazolidine-4carboxylate, pH 7.0 in phosphate buffer. The composition can be administered at a dose of 10 to 100 mg/kg/day.
The composition can be administered alone or with nutrients such as an amino acid solution.
A second example of a composition that can be administered to the patient is a capsule containing 500 r- ii i 9 U mg of L-2-oxothiazolidine-4-carboxylic acid, 167.4 mg cornstarch, 64 mg lactose and 3.6 mg ascorbic acid. The composition can be administered at a dose of one to three capsules one to three times per day.
A third example of a composition that can be administered to the patient is a lyophilized sachet containing a 1 to 5 gram cake of L-2-oxothiazolidine-4carboxylic acid which is subsequently dissclved in orange, apple, grapefruit, or other juices. The composition is taken orally one to three times per day.
SThe composition of the present invention can be administered to a patient having atherosclerosis as a treatment. Likewise, the present invention can be used to prevent the formation of atherosclerotic lesions in I 15 a patient likely to suffer same. Furthermore, the present invention can be used to prevent re-stenosis in a patient who has undergone an invasive treatment, i.e.
bypass surgery or a angioplasty, for atherosclerosis.
i By way of example, and not limitation, contemplative examples of the present invention will now be given.
EXAMPLE NO. 1 A 49 year old female with non-insulin dependent diabetes mellitus reported incidence of angina pectoris and shortness of breath to her physician. Plasma lipid peroxide level, measured as malondialdehyde, was 5.3 nmol/ml as compared to 3.7 nmol/ml in normal subjects.
The level of autoantibodies to malondialdehyde-modified low density lipoproteins was determined by solid-phase radioimmunoassay. The malondialdehyde-LDL titer was 2.93 vs. 2.06 for normal subjects. Positron Emission Tomography (PET) scan revealed a significant decrement in coronary flow reserve through the left anterior descending coronary artery.
F I
I
10 The patient was placed on a sugar free diet to control glucose levels and given 1 gram of L-2oxothiazolidine-4-cacboxylic acid (2 capsules with meals) t.i.d. The incidence of angina diminished within 2 weeks. After two months plasma malondialdehyde was down to 3.3 nmol/ml, and the autoantibody titer had declined to 2.24.
The patient was maintained on L-2-oxothiazolidine-4carboxylic acid for 1 year. Repeat PET scan indicated a definite improvement in coronary flow reserve.
EXAMPLE NO. 2 SA 43 year old male with total cholesterol level of 270 complained of severe chest pain and shortness of breath. Coronary arteriogram demonstrated 90% occlusion S 15 of the right circumflex artery. The patient was Sscheduled for angioplasty.
The patient was administat-ed 1.5 g of L-2oxothiazolidine-4-carboxylic acid t for 48 hours prior to the angioplasty. During the procedure, the occluded artery was perfused with a 3% L-2oxothiazolidine-4-carboxy3ic acid solution in phosphate buffered saline through the lumen of the balloon catheter.
Intravenous L-2-oxothiazolidine-4-carboxylic acid solution in 5% dextrose) was administered at a dose 7 of 30 mg/kg every 8 hours for 24 hours. The patient was then administered 1 gram of L-2-oxothiazolidine-4carboxylic acid t.i.d. for 30 days. Follow-up arteriography demonstrated that the treated artery was patent 1 year after the surgical event.
EXAMPLE NO. 3 A 55 year old man sffered a myocardial infarction.
Plasma cholesterol levels were 240 and plasma lipid I i -i ~1Ci 11 peroxide levels were 4.80 nmol of malondialdehyde/ml.
i Coronary arteriography indicated three vessel disease and the patient was scheduled for coronary bypass surgery.
Prior to surgery, the patient was administered a L-2-oxothiazolidine-4-carboxylic acid solution in lactated Ringer’s solution, 60 mg/kg every eight hours.
U During surgery, the patient received a sold cardioplegia solution containing 2.5 mM L-2-oxothiazolidine-4carboxylic acid.
i 10 During recovery from surgery, the patient continued V to receive the 5% L-2-oxothiazolidine-4-carboxylic acid solution in lactated Ringer’s solution, 60 mg/kg every eight hours, for 48 hours. Plasma malondialdehyde declined to 3.20 nmol/ml at the end of 48 hours. The S 15 intravenous solution was removed and oral L-2oxothiazolidine-4-carboxylic acid was administered, 1 g t.i.d. Oral treatments were continued for 60 days post surgery, then decreased to .5 g t.i.d. for the next year.
5 Follow up angiography revealed less than restenosis of any of the surgery treated vessels at one SJ’ year. Plasma lipid peroxides remained below 3.3 nmol/ml, and the titer of autoantibodies to malondialdehydemodified LDL, as measured by solid phase radioimmunoassay, remained 2.0. The patient was free of S» 25 angina at a two year follow up visit.
f It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

Claims (8)

1. A method for treating atherosclerosis comprising the step of administering to a patient having atherosclerosis a therapeutically effective amount of a product comprising L-2- j oxothiazolidine-4-carboxylic acid or a salt thereof. S2. The method of Claim 1 wherein the product is administered enterally.

3. The method of Claim 1 wherein the product is administered parenterally.

4. The method of Claim 1 wherein the product is j administered with an amino acid solution. A method for preventing atherosclerotic lesions in a patient at risk of same comprising the steps of administering to the patient a therapeutically effective amount of a product comprising L-2-oxothiazolidine-4-ca»boxylic acid or a salt thereof.

6. The method of Claim 5 wherein the product is administered enterally.

7. The method of Claim 5 wherein the product is administered parenterally. I rn -13-

8. A method for preventing re-stenosis in a patient undergoing an invasive procedure to treat atherosclerosis comprising the steps of administering to the patient prior to and after the invasive procedure a therapeutically effective amount of a product comprising L-2-oxothiazolidine-4- carboxylic acid or a salt thereof. The method of Claim 9 wherein the product is administered enterally. K 11. The method of Claim 9 wherein the product is administered parenterally.

12. The method of Claim 9 wherein the product is administered with an amino acid solution.

13. The method of Claim 9 wherein the invasive procedure is I bypass surgery. i 14. The method of Claim 9 wherein the invasive procedure is Iangioplasty. Dated this 25th day of July 1995. FREE RADICAL SCIENCES, INC. Patent Attorneys for the Applicant: PETER MAXWELL ASSOCIATES. i ABSTRACT The present invention provides a method for treating atherosclerosis. The method includes the step of administering to a patient having atherosclerosis, a non- cysteine, non-thiol composition that will stimulate the intracellular synthesis of glutathione. In an embodiment, the non-cysteine, non-thiol composition is L-2-oxothiazolidine-4-carboxylate. In an embodiment of the present invention, the present invention provides a method for preventing atherosclerotic lesions in a patient at risk of same. Furthermore, the present invention provides a maehod for preventing re-stenosis in a patient undergoing an invasive procedure to treat atherosclerosis. S:I 4I

AU38387/93A
1992-08-17
1993-05-05
Method for preventing and treating atherosclerosis

Ceased

AU663373B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US07/930,183

US5306724A
(en)

1992-08-17
1992-08-17
Method for preventing and treating atherosclerosis

US930183

1992-08-17

Publications (2)

Publication Number
Publication Date

AU3838793A

AU3838793A
(en)

1994-02-24

AU663373B2
true

AU663373B2
(en)

1995-10-05

Family
ID=25459031
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU38387/93A
Ceased

AU663373B2
(en)

1992-08-17
1993-05-05
Method for preventing and treating atherosclerosis

Country Status (7)

Country
Link

US
(1)

US5306724A
(en)

EP
(1)

EP0583865B1
(en)

JP
(1)

JPH06172175A
(en)

AU
(1)

AU663373B2
(en)

CA
(1)

CA2103644A1
(en)

DE
(1)

DE69306335T2
(en)

ES
(1)

ES2096207T3
(en)

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU666931B2
(en)

1992-08-20
1996-02-29
Transcend Therapeutics, Inc
Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate

Families Citing this family (10)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5807884A
(en)

1992-10-30
1998-09-15
Emory University
Treatment for atherosclerosis and other cardiovascular and inflammatory diseases

US5783596A
(en)

1992-10-30
1998-07-21
Emory University
Treatment for atherosclerosis and other cardiovascular and inflammatory diseases

US5380747A
(en)

1992-10-30
1995-01-10
Emory University
Treatment for atherosclerosis and other cardiovascular and inflammatory diseases

US5925658A
(en)

1995-03-02
1999-07-20
Sankyo Company, Limited
Optically active thiazolidinone derivative

US5792787A
(en)

1995-06-07
1998-08-11
Emory University
Treatment for atherosclerosis and other cardiovascular and inflammatory diseases

WO1997013149A1
(en)

1995-10-02
1997-04-10
The Trustees Of Columbia University In The City Of New York
Biochemical markers of ischemia

AU4249497A
(en)

1996-09-05
1998-03-26
Research Development Foundation
Inhibition of nuclear transcription factor nf-$g(k)b by caffeic acid phenethyl ester (cape), derivatives of cape, capsaicin (8-methyl-n-vanillyl-6-nonenamide) and resiniferatoxin

EP1223948A2
(en)

1999-09-13
2002-07-24
CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center
Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations

WO2013169355A1
(en)

2012-05-09
2013-11-14
Paringenix, Inc.
Treatment of myelosuppression

EP3258941A4
(en)

2015-02-17
2018-09-26
Cantex Pharmaceuticals, Inc.
Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction

Citations (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5095027A
(en)

1991-02-28
1992-03-10

Clintec Nutrition Co.

Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid

Family Cites Families (8)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

JPS53119866A
(en)

1977-03-25
1978-10-19
Yoshitomi Pharmaceut Ind Ltd
5-aryloxy-oxazoleakanoic acid derivatives and their preparation

US4665082A
(en)

1981-02-11
1987-05-12
Cornell Research Foundation
Cysteine delivery system

US4647571A
(en)

1981-02-11
1987-03-03
Cornell Research Foundation
Cysteine delivery composition

US4710489A
(en)

1985-04-22
1987-12-01
Cornell Research Foundation, Inc.
Glutathione delivery system

DE3722647A1
(en)

1987-07-09
1989-01-19
Gerhard Ohlenschlaeger

GALENIC USE OF A TRIPEPTID AS A MEDICINAL PRODUCT

ES2137915T3
(en)

1987-09-04
2000-01-01
Beecham Group Plc

DERIVATIVES OF TIAZOLIDINDIONA SUBSTITUTED.

US4791125A
(en)

1987-12-02
1988-12-13
Pfizer Inc.
Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents

US4798835A
(en)

1987-12-02
1989-01-17
Pfizer Inc.
dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent

1992

1992-08-17
US
US07/930,183
patent/US5306724A/en
not_active
Expired – Fee Related

1993

1993-05-05
AU
AU38387/93A
patent/AU663373B2/en
not_active
Ceased

1993-05-06
EP
EP93303526A
patent/EP0583865B1/en
not_active
Expired – Lifetime

1993-05-06
DE
DE69306335T
patent/DE69306335T2/en
not_active
Expired – Fee Related

1993-05-06
ES
ES93303526T
patent/ES2096207T3/en
not_active
Expired – Lifetime

1993-08-09
CA
CA002103644A
patent/CA2103644A1/en
not_active
Abandoned

1993-08-17
JP
JP5203491A
patent/JPH06172175A/en
active
Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5095027A
(en)

1991-02-28
1992-03-10
Clintec Nutrition Co.
Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU666931B2
(en)

1992-08-20
1996-02-29
Transcend Therapeutics, Inc
Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate

Also Published As

Publication number
Publication date

CA2103644A1
(en)

1994-02-18

AU3838793A
(en)

1994-02-24

DE69306335D1
(en)

1997-01-16

ES2096207T3
(en)

1997-03-01

EP0583865A1
(en)

1994-02-23

JPH06172175A
(en)

1994-06-21

US5306724A
(en)

1994-04-26

EP0583865B1
(en)

1996-12-04

DE69306335T2
(en)

1997-05-28

Información de contacto